Biopharma firm Alkermes' Q3 revenue beats; raises 2025 outlook

Alkermes

28/10/2025 11:15

Overview

Alkermes Q3 revenue of $394.2 mln beats analyst expectations

Company reports Q3 net income of $82.8 mln, diluted EPS at $0.49

Alkermes raises 2025 financial expectations, citing strong business momentum

Outlook

Alkermes raises 2025 revenue expectations to $1.43 bln - $1.49 bln

Company increases 2025 VIVITROL net sales forecast to $460 mln - $470 mln

Alkermes expects 2025 GAAP net income between $230 mln and $250 mln

Result Drivers

PROPRIETARY PRODUCT SALES - Increased sales of LYBALVI and ARISTADA drove revenue growth, with LYBALVI sales up 32% and ARISTADA up 16% compared to Q3 2024

MEDICAID UTILIZATION ADJUSTMENTS - Revenue growth was supported by approximately $5.0 mln for ARISTADA and $8.0 mln for VIVITROL from Medicaid utilization adjustments

STRATEGIC INITIATIVES - Proposed acquisition of Avadel Pharmaceuticals and progress in orexin 2 receptor agonist program seen as future growth drivers

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$394.20 mln
$355.30 mln (17 Analysts)
Q3 EPS
$0.49
Q3 Net Income
$82.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Alkermes Plc is $45.00, about 34% above its October 27 closing price of $29.72

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 16 three months ago

Press Release: ID:nPn6FBCHla

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)